TKT involved in a new successful IMPD application

TKT has successfully contributed to an IMPD application to the Swedish MPA for a second compound from Integrative Research Laboratories (IRL). The toxicology and safety pharmacology parts, for which TKT was responsible, were approved without comments from the MPA. First dose to man was administered in the end of February 2016. For more information: